172 related articles for article (PubMed ID: 7773504)
1. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.
Seidel A; Hasmann M; Löser R; Bunge A; Schaefer B; Herzig I; Steidtmann K; Dietel M
Virchows Arch; 1995; 426(3):249-56. PubMed ID: 7773504
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
3. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
4. Glucosamine Reverses P-Glycoprotein-Mediated Multidrug Resistance in the Daunorubicin-Resistant Human Gastric Cancer Cells.
Valinezhad Sani F; Mosaffa F; Jamialahmadi K; Palizban A
Nutr Cancer; 2020; 72(3):522-527. PubMed ID: 31290701
[TBL] [Abstract][Full Text] [Related]
5. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257.
Dietel M; Arps H; Lage H; Niendorf A
Cancer Res; 1990 Sep; 50(18):6100-6. PubMed ID: 1975514
[TBL] [Abstract][Full Text] [Related]
6. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction.
Ax W; Soldan M; Koch L; Maser E
Biochem Pharmacol; 2000 Feb; 59(3):293-300. PubMed ID: 10609558
[TBL] [Abstract][Full Text] [Related]
7. [Morphological and functional features of cytostatic drug resistance and the effects of MDR modulators].
Reymann A; Bunge A; Läer S; Dietel M
Pharmazie; 1996 Mar; 51(3):171-6. PubMed ID: 8900868
[TBL] [Abstract][Full Text] [Related]
8. Characterization and modulation of drug transport kinetics in K562 c1.6 daunorubicin-resistant cell line.
Jiang XR; Macey MG; Collins PW; Newland AC
Br J Haematol; 1994 Mar; 86(3):547-54. PubMed ID: 8043436
[TBL] [Abstract][Full Text] [Related]
9. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line.
Kim WJ; Kakehi Y; Hirai M; Arao S; Hiai H; Fukumoto M; Yoshida O
Jpn J Cancer Res; 1995 Oct; 86(10):969-77. PubMed ID: 7493917
[TBL] [Abstract][Full Text] [Related]
11. Functional intracellular P-glycoprotein.
Shapiro AB; Fox K; Lee P; Yang YD; Ling V
Int J Cancer; 1998 Jun; 76(6):857-64. PubMed ID: 9626353
[TBL] [Abstract][Full Text] [Related]
12. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
13. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.
Hurwitz SJ; Terashima M; Mizunuma N; Slapak CA
Blood; 1997 May; 89(10):3745-54. PubMed ID: 9160680
[TBL] [Abstract][Full Text] [Related]
14. Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells.
Hegewisch-Becker S; Faltz C; Hossfeld DK
Eur J Haematol; 1996; 56(1-2):12-22. PubMed ID: 8599988
[TBL] [Abstract][Full Text] [Related]
15. Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis.
Bour-Dill C; Gramain MP; Merlin JL; Marchal S; Guillemin F
Cytometry; 2000 Jan; 39(1):16-25. PubMed ID: 10655559
[TBL] [Abstract][Full Text] [Related]
16. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
Wang B; Wu M; Perchellet EM; McIlvain CJ; Sperfslage BJ; Huang X; Tamura M; Stephany HA; Hua DH; Perchellet JP
Int J Oncol; 2001 Dec; 19(6):1169-78. PubMed ID: 11713586
[TBL] [Abstract][Full Text] [Related]
17. The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.
Asschert J; de Vries E; van der Kolk D; Müller M; Vellenga E
Leukemia; 1997 May; 11(5):680-6. PubMed ID: 9180292
[TBL] [Abstract][Full Text] [Related]
18. Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.
Benderra Z; Morjani H; Trussardi A; Manfait M
Int J Oncol; 1998 Mar; 12(3):711-5. PubMed ID: 9472114
[TBL] [Abstract][Full Text] [Related]
19. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
20. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.
Fu D; Roufogalis BD
Am J Physiol Cell Physiol; 2007 Apr; 292(4):C1543-52. PubMed ID: 17122416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
